Effect of β2 -adrenergic receptor gene Arg16Gly polymorphisms on response to long-acting β2-agonist in Chinese Han asthmatic patients

Yuying Qiu; Deping Zhang; Yu Qin; Kai-Sheng Yin

doi:10.4081/mrm.2014.412

Effect of β2 -adrenergic receptor gene Arg16Gly polymorphisms on response to long-acting β2-agonist in Chinese Han asthmatic patients

Authors

Yuying Qiu Department of Respiratory Medicine, Drum Tower (Gulou) Hospital Affiliated to Nanjing University Medical School, Nanjing
Deping Zhang Department of Respiratory Medicine, Drum Tower (Gulou) Hospital Affiliated to Nanjing Univ
Yu Qin Department of Non-Communicable Chronic Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing
Kai-Sheng Yin Department of Respiratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing

DOI: https://doi.org/10.4081/mrm.2014.412

Keywords:

Asthma, β2-adrenergic receptor, Salmeterol, Long-acting β2-agonist, Fluticasone propionate, Polymorphism, Genotype

Abstract

Background: To evaluate the effect of variation of the Arg16Gly polymorphism of the β2-adrenergic receptor gene on clinical response to salmeterol administered with fluticasone propionate in Chinese Han asthmatic patients.

Methods: Moderate persistent asthmatic patients (n = 62) currently receiving short-acting β2-agonists were administered twice-daily therapy with salmeterol/fluticasone propionate 50/250 μg in a single inhaler for 12 weeks, followed by a 2-to-4-day run-out period. Using direct DNA sequencing, five single nucleotide polymorphisms (SNPs) in the promoter and coding block regions of β2-adrenergic receptor gene were determined in 62 subjects and haplotypes were combined.

Results: There was sustained and significant improvement (p < 0.001) over baseline in all measures of asthma control in subjects receiving salmeterol and fluticasone, regardless of Arg16Gly genotype. However, there was no significant difference in the improvement among three genotypes (p > 0.05). Responses to salmeterol did not appear to be modified by haplotype pairs (p > 0.05). During the run-out period, all subjects had similar decreases in measures of asthma control, with no differences between genotypes (p > 0.05).

Conclusions: Response to salmeterol does not vary with Arg16Gly polymorphisms after chronic dosing with inhaled corticosteroids in Chinese Han asthmatic patients.